Loading
GNAI2 (Guanine nucleotide-binding protein G(i) subunit alpha-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Burkitt lymphoma.
Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signalling cascades. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. Signalling by an activated GPCR promotes GDP release and GTP binding.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant. IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Non-Hodgkin Lymphoma.
In plain words · GNAI2 (Guanine nucleotide-binding protein G(i) subunit alpha-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Burkitt lymphoma.
GNAI2 (Guanine nucleotide-binding protein G(i) subunit alpha-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Burkitt lymphoma.
Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signalling cascades.
No product in this corpus aims at GNAI2 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA GNAI2: RNA low tissue specificity; high antibody staining in 12 normal tissues; highest cancer staining lymphoma (5 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P04899; CIViC gene GNAI2; IntOGen GNAI2; Human Protein Atlas GNAI2 tissue; Open Targets ENSG00000114353 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: Didsbury J.R. et al, FEBS Lett, 1987, "Human Gi protein alpha-subunit: deduction of amino acid structure from a cloned cDNA". Source.
Sources: HGNC HGNC:4385 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P04899 (protein name, function text, keywords and locations (REST API)); CIViC gene GNAI2 (2 evidence items, 0 assertions, 1 variants; diseases: Burkitt Lymphoma, EZB Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); IntOGen GNAI2 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signalling cascades. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. Signalling by an activated GPCR promotes GDP release and GTP binding. Examples of interacting GPCRs include the adenosine A1 receptor/ADORA1, CNR1, and FPR2. The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal. Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins. Location: Cytoplasm; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cell membrane; Membrane (UniProt). Locus 3p21.31 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Breast, Caudate, Cerebellum, Cervix, Colon, Endometrium, Epididymis, Gallbladder.
Medium only: endometrial cancer, liver cancer, lung cancer, melanoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"GNAI2" OR ABSTRACT:"GNAI2" OR TITLE:"G protein subunit alpha i2" OR ABSTRACT:"G protein subunit alpha i2" OR TITLE:"Guanine nucleotide-binding protein G i subunit alpha-2" OR ABSTRACT:"Guanine nucleotide-binding protein G i subunit alpha-2" OR TITLE:"GNAI2B" OR ABSTRACT:"GNAI2B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GNAI2, not a curated reading list.
Shares Burkitt lymphoma, CIViC, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Burkitt lymphoma, CIViC, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Burkitt lymphoma, CIViC, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Burkitt lymphoma, CIViC, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Burkitt lymphoma, CIViC, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Burkitt lymphoma, CIViC.
Shares Burkitt lymphoma, CIViC.
Shares Burkitt lymphoma, CIViC.